Your browser doesn't support javascript.
loading
Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab.
Verhaeghe, Alexander; Deryck, Olivier Maurice; Vanopdenbosch, Ludo J.
Afiliación
  • Verhaeghe A; University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: alexanderverhaeghe_1@hotmail.com.
  • Deryck OM; Department of Neurology, AZ Sint-Jan Brugge-Oostende AV, Ruddershove 10, 8000 Brugge, Belgium. Electronic address: olivier.deryck@azsintjan.be.
  • Vanopdenbosch LJ; Department of Neurology, AZ Sint-Jan Brugge-Oostende AV, Ruddershove 10, 8000 Brugge, Belgium. Electronic address: ludo.vanopdenbosch@azsintjan.be.
Mult Scler Relat Disord ; 3(2): 279-81, 2014 Mar.
Article en En | MEDLINE | ID: mdl-25878019
ABSTRACT
Natalizumab is a highly efficacious treatment for active relapsing-remitting multiple sclerosis, dramatically reducing both clinical and radiological signs of inflammation in most patients. The disease course after stopping treatment and especially the emergence of rebound activity are still a matter of debate. We present a case of dramatic reactivation of clinical disease activity with newly emerging pseudotumoral lesions in a patient who stopped treatment due to pregnancy. Both the clinical and radiological presentation suggest a rebound and necessitate close monitoring of patients stopping their treatment during pregnancy, even after a long period of stable disease.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mult Scler Relat Disord Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mult Scler Relat Disord Año: 2014 Tipo del documento: Article